PE20160079A1 - Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparacion, y las formulaciones que la contienen - Google Patents

Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparacion, y las formulaciones que la contienen

Info

Publication number
PE20160079A1
PE20160079A1 PE2015002679A PE2015002679A PE20160079A1 PE 20160079 A1 PE20160079 A1 PE 20160079A1 PE 2015002679 A PE2015002679 A PE 2015002679A PE 2015002679 A PE2015002679 A PE 2015002679A PE 20160079 A1 PE20160079 A1 PE 20160079A1
Authority
PE
Peru
Prior art keywords
methyl
diona
methylen
thiazolidine
pyrrol
Prior art date
Application number
PE2015002679A
Other languages
English (en)
Inventor
Jerôme Guidotti
Philippe Letellier
Flohic Alexandre Le
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20160079A1 publication Critical patent/PE20160079A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL COMPUESTO METANOSULFONATO DE 3-[(3-{[4-(4-MORFOLINILMETIL)-1H-PIRROL-2-IL]METILEN}-2-OXO-2,3-DIHIDRO-1H-INDOL-5-IL)METIL]-1,3-TIAZOLIDINA-2,4-DIONA DE FORMULA (II) DONDE EL DOBLE ENLACE DE LA POSICION 3 DEL INDOL TIENE CONFIGURACION Z O E. DICHO COMPUESTO PRESENTA EN SU DIAGRAMA DE DIFRACCION X SOBRE POLVO LOS SIGUIENTES ANGULOS DE BRAGG 2 THETA: 12,86; 15,13; 15,50; 17,70; 18,25; 18,71; 20,11; 21,46; 21,67; 21,89; 22,29; 22,58; 24,57; 25,82 Y 26,33. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER
PE2015002679A 2013-07-12 2014-07-11 Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparacion, y las formulaciones que la contienen PE20160079A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1356870A FR3008411B1 (fr) 2013-07-12 2013-07-12 Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent

Publications (1)

Publication Number Publication Date
PE20160079A1 true PE20160079A1 (es) 2016-02-06

Family

ID=50424327

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002679A PE20160079A1 (es) 2013-07-12 2014-07-11 Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparacion, y las formulaciones que la contienen

Country Status (47)

Country Link
US (2) US9925195B2 (es)
EP (1) EP3019497B1 (es)
JP (1) JP6532459B2 (es)
KR (2) KR20180028554A (es)
CN (1) CN105377843B (es)
AP (1) AP2016008976A0 (es)
AR (1) AR096882A1 (es)
AU (1) AU2014289059B2 (es)
CA (1) CA2916380C (es)
CL (1) CL2016000013A1 (es)
CR (1) CR20160012A (es)
CU (1) CU20160005A7 (es)
CY (1) CY1119259T1 (es)
DK (1) DK3019497T3 (es)
DO (1) DOP2016000005A (es)
EA (1) EA031526B1 (es)
ES (1) ES2632570T3 (es)
FR (1) FR3008411B1 (es)
GE (1) GEP201706712B (es)
GT (1) GT201600004A (es)
HK (1) HK1222172A1 (es)
HR (1) HRP20171060T1 (es)
HU (1) HUE032568T2 (es)
IL (1) IL243526B (es)
JO (1) JO3292B1 (es)
LT (1) LT3019497T (es)
MA (1) MA38759B1 (es)
MD (1) MD4507C1 (es)
ME (1) ME02735B (es)
MX (1) MX360291B (es)
MY (1) MY183197A (es)
NI (1) NI201600009A (es)
NZ (1) NZ715841A (es)
PE (1) PE20160079A1 (es)
PH (1) PH12016500017B1 (es)
PL (1) PL3019497T3 (es)
PT (1) PT3019497T (es)
RS (1) RS55945B1 (es)
RU (1) RU2680826C9 (es)
SA (1) SA516370388B1 (es)
SG (1) SG11201510570YA (es)
SI (1) SI3019497T1 (es)
TN (1) TN2015000566A1 (es)
TW (2) TWI554510B (es)
UA (1) UA114041C2 (es)
UY (1) UY35629A (es)
WO (1) WO2015004395A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245270B2 (en) * 2013-07-12 2019-04-02 Les Laboratoires Servier Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
AU2002226877B2 (en) * 2000-10-17 2006-01-12 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
ATE302771T1 (de) * 2001-12-27 2005-09-15 Theravance Inc Indolinon-derivative als protein-kinasehemmer
JP2007509173A (ja) * 2003-10-24 2007-04-12 シエーリング アクチエンゲゼルシャフト インドリノン誘導体類及び疾病状態、例えば癌の処理へのそれらの使用
TWI403493B (zh) * 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
UY35629A (es) 2015-01-30
AU2014289059B2 (en) 2017-05-25
HK1222655A1 (zh) 2017-07-07
ES2632570T3 (es) 2017-09-14
TW201630906A (zh) 2016-09-01
MA38759A1 (fr) 2018-01-31
TWI554510B (zh) 2016-10-21
MD4507C1 (ro) 2018-03-31
CA2916380C (fr) 2017-11-21
SG11201510570YA (en) 2016-01-28
WO2015004395A1 (fr) 2015-01-15
TN2015000566A1 (fr) 2017-04-06
EA201600101A1 (ru) 2016-06-30
MA38759B1 (fr) 2018-09-28
CY1119259T1 (el) 2018-02-14
GT201600004A (es) 2018-09-28
TW201504236A (zh) 2015-02-01
KR20160030399A (ko) 2016-03-17
AP2016008976A0 (en) 2016-01-31
MX2016000332A (es) 2016-05-09
US20160151378A1 (en) 2016-06-02
GEP201706712B (en) 2017-07-25
MY183197A (en) 2021-02-18
DK3019497T3 (en) 2017-08-07
FR3008411B1 (fr) 2015-07-03
CA2916380A1 (fr) 2015-01-15
CU20160005A7 (es) 2016-05-30
JO3292B1 (ar) 2018-09-16
RU2680826C2 (ru) 2019-02-28
MD20160003A2 (ro) 2016-06-30
US9925195B2 (en) 2018-03-27
JP2016523953A (ja) 2016-08-12
HRP20171060T1 (hr) 2017-10-06
AR096882A1 (es) 2016-02-03
PL3019497T3 (pl) 2017-09-29
CN105377843A (zh) 2016-03-02
HK1222172A1 (zh) 2017-06-23
CL2016000013A1 (es) 2016-08-12
IL243526A0 (en) 2016-02-29
EP3019497B1 (fr) 2017-04-12
SI3019497T1 (sl) 2017-07-31
DOP2016000005A (es) 2016-12-15
PH12016500017B1 (en) 2019-06-26
CR20160012A (es) 2016-02-08
EA031526B1 (ru) 2019-01-31
UA114041C2 (xx) 2017-04-10
IL243526B (en) 2019-09-26
LT3019497T (lt) 2017-05-25
KR20180028554A (ko) 2018-03-16
EP3019497A1 (fr) 2016-05-18
NZ715841A (en) 2019-04-26
PH12016500017A1 (en) 2016-04-18
PT3019497T (pt) 2017-05-15
NI201600009A (es) 2016-02-11
HUE032568T2 (hu) 2017-09-28
AU2014289059A1 (en) 2016-02-04
US20180207171A1 (en) 2018-07-26
MX360291B (es) 2018-10-29
RS55945B1 (sr) 2017-09-29
SA516370388B1 (ar) 2017-12-14
CN105377843B (zh) 2019-03-05
RU2016104642A (ru) 2017-08-17
JP6532459B2 (ja) 2019-06-19
ME02735B (me) 2017-10-20
FR3008411A1 (fr) 2015-01-16
RU2680826C9 (ru) 2019-03-01
MD4507B1 (ro) 2017-08-31

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
JO3425B1 (ar) مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
PE20160605A1 (es) Formulaciones de inhibidores de la syk
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
EA201790661A2 (ru) Ингибиторы вируса гепатита c
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
CR20160016A (es) Pirazolpiridinas sustituidas
PE20151607A1 (es) Formulaciones de compuestos organicos
ECSP16096831A (es) Derivados de naftiridinadiona
MX2015012386A (es) Inhibidores de la cinasa cdk9.
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
PE20160079A1 (es) Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparacion, y las formulaciones que la contienen
UY34986A (es) Derivados de diazepinona
ITUB20160650A1 (it) Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
UA102010C2 (ru) Комбинация активных ингредиентов, которая содержит нестероидное противовоспалительное лекарственное средство и производное колхикозида
UY35324A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol